Skip to main content
Figure 4 | Journal of Hematology & Oncology

Figure 4

From: HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas

Figure 4

Effect of HDM2 inhibition in normal B-lymphocytes derived from healthy donors. A) Isolated B-lymphocytes from normal donors were exposed to HDM2 SMIs for up to 48 h. Neither HDM2 SMI induced a significant decrease in cell viability compared to untreated cells (control). B) The inactive Nutlin-3 analog, Nutlin-3b, was ineffective in significantly decreasing cell viability in all 4 cell lines for up to 72 h. Columns and error bars represent Mean ± S.D. of three independent experiments.

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us